Ally Bridge Backs Go-Private Deal of Chinese Pharmaceutical Firm Luoxin
March 15, 2017 — 03:15 CST
This Data Is Locked!
This area is available only to Subscribers.
Ally Bridge Group, a Hong Kong-based healthcare-focused private equity firm, has proposed a HK$2.34 billion (US$301 million) privatization deal to take Hong Kong-listed Shangdong Luoxin... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals